Jay Lichter sold $178k of JANX
owner at Janux Therapeutics, Inc.. 3,815 shares at an average of $46.68, traded Sep 13, 2024, filed Oct 24, 2024.
Score components
- +12Role10% owner
- +12Trade size$178k at market
- +10Share of holdings soldSold 35% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -5.6%, 3m -16.4%, 6m -39.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-025601, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 13, 2024 | MOption exercise Common Stock | +1,868 | $17.00 | $32k | 8,868 | Oct 24, 2024 |
| Sep 13, 2024 | MOption exercise Common Stock | +778 | $10.73 | $8,348 | 9,646 | Oct 24, 2024 |
| Sep 13, 2024 | MOption exercise Common Stock | +778 | $13.22 | $10k | 10,424 | Oct 24, 2024 |
| Sep 13, 2024 | MOption exercise Common Stock | +391 | $39.80 | $16k | 10,815 | Oct 24, 2024 |
| Sep 13, 2024 | SOpen-market sale Common Stock | -3,815 | $46.68 | $178k | 7,000 | Oct 24, 2024 |
| Sep 13, 2024 | MOption exercise Stock Option (right to buy)derivative | -1,868 | $0.00 | $0 | 27,138 | Oct 24, 2024 |
| Sep 13, 2024 | MOption exercise Stock Option (right to buy)derivative | -778 | $0.00 | $0 | 11,308 | Oct 24, 2024 |
| Sep 13, 2024 | MOption exercise Stock Option (right to buy)derivative | -778 | $0.00 | $0 | 11,308 | Oct 24, 2024 |
| Sep 13, 2024 | MOption exercise Stock Option (right to buy)derivative | -391 | $0.00 | $0 | 7,682 | Oct 24, 2024 |
Related signals
Other insiders at Janux Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Janux Therapeutics, Inc. | Andrew Hollman Meyer Chief Business Officer | $110k 3,333 shares | -4% | |
| 0Weak | Janux Therapeutics, Inc. | Andrew Hollman Meyer Chief Business Officer | $100k 3,333 shares | -4% | |
| 3Weak | Janux Therapeutics, Inc. | Andrew Hollman Meyer Chief Business Officer | $501k 16,665 shares | -17% | |
| 0Weak | Janux Therapeutics, Inc. | Andrew Hollman Meyer Chief Business Officer | $107k 3,333 shares | -4% | |
| 0Weak | Janux Therapeutics, Inc. | Andrew Hollman Meyer Chief Business Officer | $100k 3,334 shares | -4% | |
| 43Moderate | JANXbuy Janux Therapeutics, Inc. | Ra Capital Management, L.p. director, owner | $25M 824,041 shares | +9% | |
| 0Weak | Janux Therapeutics, Inc. | Andrew Hollman Meyer Chief Business Officer | $107k 3,334 shares | -4% | |
| 0Weak | Janux Therapeutics, Inc. | Andrew Hollman Meyer Chief Business Officer | $141k 3,334 shares | -4% | |
| 27Weak | Janux Therapeutics, Inc. | David Alan Campbell President and CEO | $300k 5,000 shares | -2% | |
| 29Weak | Janux Therapeutics, Inc. | Andrew Hollman Meyer Chief Business Officer | $732k 13,334 shares | -14% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.